যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - ciclosporin - oral capsule - 50mg

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: corn oil peg-6 esters; ethanol; gelatin; glycerol; titanium dioxide; iron oxide yellow; maize oil; purified water; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate - as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. extended indications as at 15 october 1993: for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired. indications as at 11 february 1994 from dr j. mcginness: 1. as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and hart allogeneic transplantation. 2. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failued, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired. 3. for the treatment of severe, active rheumatoid arthritis i

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

le vet beheer b.v. - ciclosporin - oral solution - 50 mg/ml - ciclosporin - canine, feline - miscellaneous

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

le vet beheer b.v. - ciclosporin - oral solution - 50 milligram(s)/millilitre - zzz ciclosporin - cats, dogs - miscellaneous

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

novartis ireland limited - ciclosporin - capsule, soft - 50 milligram(s) - calcineurin inhibitors; ciclosporin

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

novartis ireland limited - ciclosporin - concentrate for solution for infusion - 50 milligram(s)/millilitre - calcineurin inhibitors; ciclosporin

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

novartis ireland limited - ciclosporin - capsule, soft - 50 milligram(s) - calcineurin inhibitors; ciclosporin

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: tricaprin; peg-40 hydrogenated castor oil; gelatin; ethyl lactate; purified water; lecithin; sorbitan oleate; iron oxide black; glycerol; polysorbate 20; titanium dioxide - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: gelatin; polysorbate 20; iron oxide black; tricaprin; ethyl lactate; sorbitan oleate; peg-40 hydrogenated castor oil; glycerol; lecithin; titanium dioxide; purified water - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: iron oxide black; purified water; tricaprin; sorbitan oleate; gelatin; polysorbate 20; ethyl lactate; titanium dioxide; glycerol; lecithin; peg-40 hydrogenated castor oil - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).